<DOC>
	<DOCNO>NCT01416259</DOCNO>
	<brief_summary>This Phase I study perform double-blind , randomize , crossover design healthy male female subject . The central ECG laboratory blind treatment . Every effort make enroll equal number male female study . Eligible subject participate screen phase ( within 28 day dose day ) , treatment phase final visit , conduct discharge study . Study duration 32 day total approximately 12 day confinement . During rest ECG period , 12-lead digital ECGs extract continuous telemetry select time point assess potential ECG effect . Blood sample PK evaluation collect conjunction ECG time point .</brief_summary>
	<brief_title>A Phase I Study Effects APF530 Exposure , Granisetron Moxifloxacin</brief_title>
	<detailed_description />
	<mesh_term>Granisetron</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Subjects good health age 1850 year weigh least 50 kg ( 110 pound ) body mass index 1832 kg/m2 inclusive capable understand comply protocol sign informed consent history drug abuse current smoker know hypersensitivity Moxifloxacin granisetron history presence clinically significant abnormal 12lead ECG ECG QTc Bazett 's correction &gt; 450 m men , &gt; 470 ms woman screen ECG PR &gt; 240 m , QRS &gt; 110 ms history prolongation QT interval family history Long QT Syndrome cardiac disease may use medication consume food contraindicate protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>QTc Prolongation</keyword>
</DOC>